A Long-term Follow-up Study in Patients With Hemoglobinopathy Who Received Autologous CD34+ Edited Hematopoietic Stem Cells
Status: Recruiting
Location: See all (17) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed for 13 years (a total of 15 years after receiving BEAM-101).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 14
Maximum Age: 37
Healthy Volunteers: f
View:
• Have received BEAM-101 in Study BTX-AUT-001 and are in the process of completing that study's end-of-study (EOS) visit.
• Provide signed, written informed consent according to local institutional review board (IRB)/independent ethics committee (IEC) and institutional requirements.
Locations
United States
Alabama
University of Alabama at Birmingham
NOT_YET_RECRUITING
Birmingham
Arizona
Phoenix Children's Hospital
NOT_YET_RECRUITING
Phoenix
Florida
Mayo Clinic Florida
NOT_YET_RECRUITING
Jacksonville
Georgia
Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston
NOT_YET_RECRUITING
Atlanta
Massachusetts
Boston Children's Hospital
RECRUITING
Boston
Michigan
Henry Ford Cancer Center
NOT_YET_RECRUITING
Detroit
Minnesota
University of Minnesota
NOT_YET_RECRUITING
Minneapolis
Missouri
Washington University School of Medicine in St. Louis
NOT_YET_RECRUITING
St Louis
New Jersey
Hackensack University Medical Center
NOT_YET_RECRUITING
Hackensack
New York
Columbia University Irving Medical Center
NOT_YET_RECRUITING
New York
Ohio
The Clevland Clinic Foundation
NOT_YET_RECRUITING
Cleveland
University Hospitals Clevland Medical Center
NOT_YET_RECRUITING
Cleveland
Pennsylvania
Children's Hospital of Philadelphia
NOT_YET_RECRUITING
Philadelphia
South Carolina
Medical University of South Carolina
NOT_YET_RECRUITING
Charleston
Tennessee
St. Jude Children's Research Hospital
NOT_YET_RECRUITING
Memphis
The Children's Hospital at TriStar Centennial
NOT_YET_RECRUITING
Nashville
Wisconsin
Medical College of Wisconsin
NOT_YET_RECRUITING
Milwaukee
Contact Information
Primary
Medical Information
clinicalinfo@beamtx.com
+1 857-327-8641
Time Frame
Start Date: 2025-12-15
Estimated Completion Date: 2043-02-12
Participants
Target number of participants: 50
Treatments
BTX-101-002 Long-term Follow-up on Patients who received BEAM-101
All participants who received BEAM-101 in the BTX-AUT-001 trial will be asked to participate in this long-term follow-up study
Related Therapeutic Areas
Sponsors
Leads: Beam Therapeutics Inc.